Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin's Vazkepa, clearing the path for GPs to start prescribing the drug in up to 425,000 NHS patients at high
Around 425,000 people in England and Wales with cardiovascular disease who are at risk of a secondary stroke or heart attack, could be eligible for treatment with Amarin's Vazkepa, followin